and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet, which read: “We are excited to announce insulin is free now.” ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling ...

Novo Nordisk shares have dropped significantly in ... And although the company's free cash flow was negative for the quarter, at -$527.8 million, full-year FCF was strong at $10.25 billion ...

Moreover, free cash flow turned negative at minus DKK14.7 billion, largely due to heavy capital expenditures and the Catalent acquisition. Despite these challenges, Novo Nordisk remains well ...

Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial statements free of charge upon request to investor-relations@novon Bagsværd, 5 February 2025 - Financial ...

Novo Nordisk’s annual results are out and they show the Danish pharmaceutical juggernaut earnt 290.4 billion Danish kroner last year (A$64 billion) — up 25%. Novo Nordisk boasts 45 million ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 diabetes, has started phase III trials. If it reaches the market, the oral formulation ...